Arcus Biosciences Price to Book Ratio 2017-2021 | RCUS

Historical price to book ratio values for Arcus Biosciences (RCUS) over the last 10 years. The current price to book ratio for Arcus Biosciences as of December 07, 2021 is 5.92.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Arcus Biosciences Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-06 43.83 5.67
2021-09-30 34.87 $7.72 4.51
2021-06-30 27.46 $8.47 3.24
2021-03-31 28.08 $9.37 3.00
2020-12-31 25.96 $7.71 3.37
2020-09-30 17.14 $8.39 2.04
2020-06-30 24.74 $7.27 3.40
2020-03-31 13.88 $3.06 4.54
2019-12-31 10.10 $3.57 2.83
2019-09-30 9.10 $3.87 2.35
2019-06-30 7.95 $4.29 1.85
2019-03-31 12.49 $4.98 2.51
2018-12-31 10.77 $5.28 2.04
2018-09-30 13.94 $5.51 2.53
2018-06-30 12.24 $5.73 2.14
2018-03-31 15.44 $6.00 2.57
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.210B $0.078B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71